PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 88 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers February 3, 2026 Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Tackling under-representation of Black data scientists in cancer research November 7, 2022 Load more HOT NEWS 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A... Urine test for bladder cancer being developed FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer March is Colon Cancer Awareness Month
